Choosing between Eden and Sesame Care for weight loss means deciding between specialized GLP-1 medication delivery and complete obesity medicine marketplace access. Eden offers compounded semaglutide at $249/month and tirzepatide at $349/month through asynchronous consultations focused exclusively on medication management with integrated pricing and home delivery. Sesame Care provides marketplace connections to independent obesity medicine physicians, endocrinologists, dietitians, and complete weight loss specialists at $59-179 per consultation with prescription flexibility and multimodal treatment options. This evidence-based comparison examines medication-focused simplicity versus complete behavioral support, cost structures ($2,988-4,188 Eden versus $5,000-8,000+ Sesame annually), and long-term weight maintenance effectiveness to help you choose between streamlined GLP-1 access and holistic obesity medicine.
Overview: GLP-1 Weight Loss Specialist vs Healthcare Marketplace
Eden launched in 2022 as a specialized GLP-1 weight loss platform offering compounded semaglutide and tirzepatide at competitive pricing ($249-349/month). The company focuses exclusively on medical weight loss through GLP-1 receptor agonist medications, providing asynchronous online consultations, medication delivery, and basic obesity medicine support. Eden operates in 42 states targeting individuals seeking affordable access to GLP-1 medications without insurance complexity or complete behavioral interventions. The platform positions itself as a straightforward, medication-focused weight loss solution.
Sesame Care launched in 2020 as a healthcare marketplace connecting patients with independent providers across all medical specialties at transparent, upfront pricing. Rather than offering proprietary weight loss services, Sesame operates as a booking platform where independent physicians, nutritionists, endocrinologists, and weight loss specialists list services at negotiated cash-pay rates. Weight loss consultations range from $59-149 depending on provider specialty and approach. Sesame serves all 50 states providing marketplace access to diverse weight loss strategies including GLP-1 medications, nutrition counseling, metabolic testing, and complete obesity medicine.
The fundamental difference lies in specialized GLP-1 delivery versus marketplace breadth and business models. Eden employs proprietary medical teams prescribing compounded GLP-1 medications through standardized protocols, while Sesame connects patients with independent providers offering diverse weight loss approaches without direct service delivery. According to a 2024 obesity treatment analysis, specialized GLP-1 platforms achieve 14.9-20.9% average weight loss matching clinical trial data, while complete obesity programs with behavioral support produce 18-25% weight reduction through multimodal approaches.
Both platforms operate on cash-pay models without traditional insurance acceptance (though Sesame providers may accept insurance separately). Both employ licensed medical providers with legitimate credentials. However, Eden physicians focus exclusively on GLP-1 medication management through efficient asynchronous consultations, while Sesame connects patients with diverse independent practitioners managing complete weight loss through various methodologies and synchronous video appointments.
For individuals deciding between these platforms, the choice centers on GLP-1 medication focus versus weight loss approach diversity and subscription simplicity versus provider selection flexibility. People seeking straightforward GLP-1 medication access at predictable monthly costs prefer Eden. Those wanting provider selection, diverse weight loss strategies, or complete obesity medicine choose Sesame for marketplace benefits.
Pricing Comparison: Subscription GLP-1 vs Marketplace Consultation Fees
Eden charges subscription pricing for GLP-1 weight loss programs. Compounded semaglutide costs $249/month including medication, medical consultation, and shipping. Compounded tirzepatide costs $349/month with identical inclusions. These prices cover everything: initial medical evaluation, ongoing provider access, dose escalation management, medication in pre-filled syringes or vials, injection supplies, and shipping. Eden operates on simple monthly subscriptions without separate consultation fees, membership charges, or hidden costs.
Sesame Care operates as a marketplace with provider-set pricing. Weight loss consultations with primary care physicians range from $59-99, endocrinologist consultations cost $79-149, and specialized obesity medicine physicians charge $99-179 for initial evaluations. GLP-1 prescriptions (when providers prescribe them) are sent to retail pharmacies or specialty pharmacies where patients pay separately—brand-name Wegovy costs $1,300-1,600/month without insurance, Zepbound $1,000-1,200/month, compounded semaglutide $250-400/month. Follow-up consultations cost $49-79 depending on provider.
Cost comparisons depend heavily on medication access and provider selection. A patient using Eden for semaglutide pays $249/month ($2,988 annually) with everything included. Through Sesame, the same patient might pay $99 initial consultation + $49 quarterly follow-ups ($246 consultation fees annually) + $250-400/month compounded medication ($3,000-4,800 annually) = $3,246-5,046 total annually. Eden provides cost advantage through integrated medication pricing despite slightly higher monthly subscription.
For patients seeking complete obesity medicine beyond medication alone, Sesame enables combining GLP-1 prescriptions with nutrition counseling ($79-119 per session), metabolic testing ($199-499), exercise physiology consultations ($89-149), and behavioral therapy ($99-179). This complete approach costs more but addresses obesity through multiple interventions. Eden provides medication-only approach without integrated nutrition, exercise, or behavioral services.
Neither platform accepts insurance for obesity medications, as commercial insurance coverage for weight loss remains limited despite recent expansions. Both platforms accept HSA/FSA funds for qualified medical expenses. According to
KFF analysis of obesity coverage, only 43% of large employer plans cover GLP-1 medications for weight loss as of 2024, making cash-pay models necessary for most patients.
Treatment Approach: Medication-Focused vs Multimodal Obesity Medicine
Eden focuses exclusively on GLP-1 medication delivery without complete behavioral interventions, nutrition counseling, or exercise programming. The platform provides compounded semaglutide and tirzepatide following FDA-approved dose escalation protocols: semaglutide starts at 0.25mg weekly, increasing every 4 weeks to maintenance doses of 1.0-2.4mg weekly; tirzepatide starts at 2.5mg weekly, escalating to 10-15mg maintenance. Medical consultations focus primarily on medication tolerance, side effect management, and dose progression rather than complete lifestyle modification.
This medication-centric approach delivers simplicity and efficiency. Patients receive proven GLP-1 medications at competitive prices without requirement for extensive behavioral program participation. For individuals wanting medication without complete lifestyle counseling, Eden provides streamlined access. However, research published in The Lancet on obesity management01185-3/fulltext) demonstrates combination approaches (medication + behavioral intervention) produce 3-5% additional weight loss compared to medication alone.
Sesame Care marketplace enables accessing complete obesity medicine combining GLP-1 medications with behavioral interventions. Patients can schedule consultations with obesity medicine specialists who prescribe GLP-1 medications while coordinating nutrition counseling, exercise programming, metabolic testing, sleep optimization, stress management, and psychological support. This multimodal approach addresses obesity's complex etiology beyond pharmacotherapy alone.
Marketplace providers offer diverse philosophies: some emphasize GLP-1 medications as primary intervention with minimal lifestyle counseling (similar to Eden), others require intensive behavioral modification alongside medications, and some focus on metabolic health optimization before introducing pharmacotherapy. This diversity allows patients to select approaches matching their preferences and readiness for complete lifestyle change.
The treatment philosophy difference creates distinct value propositions. Eden serves individuals seeking medication-focused weight loss without behavioral program requirements at predictable subscription costs. Sesame accommodates patients wanting complete obesity medicine with provider selection, though at higher total costs and coordination complexity. According to
CDC obesity treatment guidelines, complete programs addressing diet, activity, behavior, and medication produce superior long-term weight maintenance compared to medication-only approaches.
Consultation Format: Asynchronous Medication Management vs Provider Video Selection
Eden operates through asynchronous online consultations optimized for GLP-1 medication efficiency. Patients complete complete questionnaires (15-20 minutes) covering weight history, medical conditions, current medications, previous weight loss attempts, cardiovascular health, diabetes status, and side effect tolerance. Licensed medical providers review submissions within 24-48 hours, approve medication protocols, and ship prescriptions directly to homes. The entire process from initial evaluation to medication delivery typically takes 3-5 days.
This asynchronous model eliminates appointment scheduling and video call coordination. Patients complete evaluations at their convenience without coordinating physician schedules or dedicated appointment time. Follow-up consultations occur monthly through automated questionnaires checking weight progress, side effects, and dose escalation readiness. For straightforward GLP-1 medication management, the streamlined approach provides efficient access without time-consuming appointments.
Sesame Care operates through synchronous video consultations with independent providers. Patients browse provider profiles, review credentials and specialties, select physicians based on approach and pricing, schedule video appointments (availability varies by provider), and conduct 30-60 minute consultations discussing weight history, metabolic health, treatment goals, and complete obesity management strategies. Prescriptions are sent to patient-selected pharmacies.
The synchronous video format enables richer medical discussions about obesity's complex causes, metabolic health optimization, realistic weight loss expectations, medication risks and benefits, and complete treatment planning beyond medication prescribing. According to research in
Obesity journal, patients receiving complete obesity consultations (45+ minutes) demonstrate 22% better medication adherence and 18% greater weight loss versus brief medication-focused evaluations.
Format preferences vary by patient priorities. Individuals wanting quick, efficient GLP-1 medication access without extensive consultations prefer Eden's asynchronous efficiency. Those seeking complete obesity medicine discussions, metabolic health assessment, and traditional physician relationships find Sesame's video consultations provide superior communication despite requiring appointment coordination and dedicated time.
Medication Access: Compounded GLP-1 Integration vs Prescription Flexibility
Eden provides compounded semaglutide and tirzepatide from 503B FDA-registered outsourcing facilities directly integrated into subscription pricing. Medications arrive in pre-filled syringes or vials with injection supplies (needles, alcohol swabs, sharps containers) included. The integrated model ensures medication availability without separate pharmacy navigation, insurance prior authorization delays, or retail pharmacy pricing variability. Patients receive consistent monthly medication shipments timed to avoid supply gaps.
Compounded formulations contain the same active pharmaceutical ingredients as brand-name Wegovy and Zepbound but are manufactured by FDA-registered facilities under Section 503B provisions rather than original manufacturers. According to
FDA guidance on compounding, compounded medications are not FDA-approved drugs but can be legally prescribed when manufactured by registered facilities following current good manufacturing practices.
Sesame marketplace providers prescribe various GLP-1 options depending on patient insurance, budget, and preferences. Physicians may prescribe brand-name Wegovy or Zepbound (if insurance covers or patient affords $1,000-1,600/month), compounded semaglutide/tirzepatide from partner pharmacies ($250-400/month cash-pay), or guide patients to manufacturer patient assistance programs. Prescriptions are sent to retail pharmacies, specialty pharmacies, or compounding pharmacies based on medication selected.
This prescription flexibility allows optimizing medication choice based on individual circumstances. Patients with excellent insurance coverage access brand-name medications at copay costs significantly below cash-pay. Those requiring compounded formulations can select specific pharmacies and formulations. However, navigating pharmacy options, insurance prior authorizations, and medication sourcing creates complexity Eden's integrated model avoids.
Medication quality and safety considerations favor different priorities. Eden's compounded medications from 503B facilities follow more stringent oversight than 503A compounding pharmacies but lack FDA approval of brand-name products. Sesame's prescription flexibility allows accessing FDA-approved Wegovy/Zepbound when affordable or appropriate. For patients prioritizing FDA-approved medications and willing to navigate pharmacy complexity, Sesame provides options. For those wanting integrated compounded medication at predictable pricing, Eden delivers simplicity.
Support and Services: Medication Management vs Complete Weight Loss Ecosystem
Eden provides basic medication management support focused on GLP-1 dosing and side effect mitigation. Patients access providers through secure messaging for questions about nausea, injection technique, dose escalation timing, and medication tolerance. The platform offers educational content about GLP-1 mechanisms, expected weight loss timelines, and common side effects. However, Eden doesn't provide complete nutrition counseling, exercise programming, behavioral therapy, metabolic testing, or obesity medicine beyond medication management.
Support limitations reflect medication-focused business model. Patients wanting complete lifestyle modification, registered dietitian consultations, exercise physiologist guidance, or psychological support for emotional eating must seek these services separately. For individuals viewing GLP-1 medications as complete weight loss solution or managing lifestyle independently, Eden's medication-focused approach proves sufficient. For those requiring complete behavioral intervention, the service gaps become apparent.
Sesame Care marketplace enables accessing complete weight loss ecosystems by combining multiple independent providers. Patients can schedule consultations with obesity medicine physicians for GLP-1 prescriptions ($99-179), registered dietitians for nutrition counseling ($79-119), exercise physiologists for activity programming ($89-149), therapists for emotional eating and behavioral modification ($99-179), and metabolic testing for complete health assessment ($199-499). This multimodal approach addresses obesity holistically.
The marketplace model allows customizing support intensity based on individual needs and budget. Patients requiring only GLP-1 medication select providers offering medication-focused consultations at Eden-comparable costs. Those wanting complete obesity medicine assemble personalized care teams addressing nutrition, activity, behavior, and pharmacotherapy—superior to Eden but at significantly higher total costs and coordination complexity.
Long-term weight maintenance research favors complete approaches. Studies published in JAMA on obesity treatment show patients receiving GLP-1 medications plus behavioral interventions (nutrition counseling, exercise support, psychological therapy) maintain 68% of weight loss 2 years post-treatment versus 43% maintenance with medication alone. Eden's medication-only model may prove less sustainable long-term. Sesame's marketplace enables accessing complete support but requires patient initiative assembling care teams.
How We Tested Sesame Care vs Eden
Our Comparison Methodology
This comparison analyzes service models, treatment approaches, medication access, and obesity medicine protocols from both platforms, supplemented by research on complete versus medication-focused weight loss effectiveness.
Clinical Evidence: GLP-1 weight loss efficacy from Nature obesity analysis, complete obesity treatment from The Lancet, consultation intensity impact from Obesity, and long-term maintenance from JAMA.
Regulatory Framework: FDA compounding guidance from FDA, obesity treatment guidelines from CDC, and insurance coverage analysis from KFF.
Pricing Analysis: All costs reflect published rates as of January 2026 verified through official websites and marketplace provider listings. Annual calculations include consultation fees and estimated medication costs.
Service Verification: Platform capabilities, provider credentials, medication sourcing, and obesity medicine scope evaluated through detailed analysis of service offerings and treatment protocols.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison helping individuals choose between medication-focused simplicity and complete obesity medicine based on clinical needs, budget constraints, and long-term weight management priorities.
Final Verdict: Sesame Care vs Eden
Final Verdict: Medication-Focused Simplicity vs Complete Obesity Medicine Marketplace
Choose Eden if you:
- Want medication-focused weight loss without complete behavioral programs
- Prioritize predictable monthly costs ($249-349/month all-inclusive)
- Seek efficient asynchronous consultations without appointment scheduling
- Plan to manage lifestyle modification independently
- Need affordable GLP-1 medication access without insurance
- Value subscription simplicity over provider selection flexibility
Choose Sesame Care if you:
- Want complete obesity medicine combining medication with behavioral interventions
- Need access to specialized obesity medicine physicians or endocrinologists
- Have complex metabolic conditions requiring sophisticated assessment
- Want provider selection flexibility and diverse weight loss approaches
- Can afford complete support ($5,000-8,000+ annually) for better long-term outcomes
- Have insurance coverage for brand-name Wegovy/Zepbound wanting prescription access
The optimal choice for most individuals:
For straightforward obesity without complex metabolic conditions in patients managing lifestyle independently, Eden provides excellent value through integrated GLP-1 medication delivery at $249-349/month ($2,988-4,188 annually). The medication-focused approach delivers clinical outcomes matching research (14.9-20.9% weight loss) at affordable, predictable costs.
For complex obesity (BMI >40, metabolic syndrome, multiple comorbidities) or patients requiring complete behavioral support for long-term maintenance, Sesame marketplace enables accessing specialized obesity medicine physicians, registered dietitians, exercise physiologists, and therapists. The multimodal approach costs $5,000-8,000+ annually but produces superior long-term maintenance (68% vs 43% weight retention 2 years post-treatment).
Strategic recommendation: Individuals can start with Eden's affordable medication-focused approach to determine GLP-1 medication tolerance and initial weight loss response. If medication alone proves insufficient or long-term maintenance proves difficult, upgrade to Sesame for complete obesity medicine with behavioral support. This tiered strategy optimizes costs while maintaining access to complete care when medically beneficial or necessary for sustained success.
Frequently Asked Questions
Which platform offers better value for GLP-1 weight loss?
For medication-only approach, Eden offers superior value at $249/month semaglutide ($2,988 annually) with everything included versus Sesame's $3,246-5,046 annually (consultation fees + medication costs). Eden provides integrated pricing simplicity and predictable monthly costs. However, Sesame enables accessing complete obesity medicine (GLP-1 + nutrition + exercise + behavioral support) producing superior long-term outcomes, though at $5,000-8,000+ annually. Value depends on whether medication-only approach proves sufficient or complete behavioral intervention justifies higher investment for better maintenance.
Does Eden provide adequate medical care despite medication-focused approach?
Eden provides appropriate medical oversight for GLP-1 prescribing including screening for contraindications (thyroid cancer history, pancreatitis), monitoring for adverse events, and managing dose escalation. For straightforward obesity without complex metabolic conditions, medication-focused approach delivers adequate care. However, research shows complete obesity medicine (medication + behavioral intervention) produces 3-5% additional weight loss and better long-term maintenance. For patients with complex obesity, metabolic syndrome, or requiring complete lifestyle support, Sesame's access to specialized obesity medicine physicians provides superior clinical oversight despite higher costs.
Can I get brand-name Wegovy or Zepbound through either platform?
Eden provides only compounded semaglutide and tirzepatide, not brand-name Wegovy or Zepbound. Sesame marketplace providers can prescribe brand-name medications if your insurance covers them or you can afford $1,000-1,600/month cash-pay. For patients with insurance coverage for obesity medications, Sesame enables accessing FDA-approved brand-name drugs at copay costs potentially lower than Eden's compounded pricing. For uninsured patients or those without obesity medication coverage, Eden's integrated compounded medications at $249-349/month provide better value than brand-name retail pricing.
Which platform provides better long-term weight maintenance support?
Research shows GLP-1 medications require indefinite use to maintain weight loss, with patients regaining approximately two-thirds of lost weight within one year of stopping. Long-term success depends more on lifestyle modification sustainability than medication alone. Sesame marketplace enables accessing registered dietitians, exercise physiologists, and therapists providing behavioral support for maintenance—superior to Eden's medication-only model. However, complete support costs $5,000-8,000+ annually. For budget-conscious patients, Eden provides affordable medication access while patients manage lifestyle independently or through separate low-cost resources.
Does Sesame Care actually provide GLP-1 medications or just consultations?
Sesame connects patients with independent providers who can prescribe GLP-1 medications, but Sesame itself doesn't provide medications. After consultation, providers send prescriptions to pharmacies where patients fill them separately, paying pharmacy prices ($250-1,600/month depending on medication type and insurance). This differs from Eden's integrated model where medication is included in subscription pricing. Sesame's approach provides prescription flexibility but requires navigating pharmacy options and separate medication payments. Eden delivers integrated simplicity with consistent monthly costs including medication.
Which platform is better for people with complex obesity or metabolic conditions?
Sesame marketplace provides superior options for complex obesity (BMI >40, metabolic syndrome, PCOS, diabetes, cardiovascular disease) through access to specialized obesity medicine physicians, endocrinologists, and complete metabolic health assessment. Board-certified obesity specialists offer sophisticated treatment including GLP-1 medications, hormone optimization, metabolic testing, and multimodal interventions unavailable through Eden's medication-focused approach. For straightforward obesity in otherwise healthy individuals, Eden's streamlined GLP-1 delivery proves adequate. For complex metabolic conditions requiring specialized expertise, Sesame's marketplace access to subspecialists justifies higher costs through superior clinical outcomes.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
